NCT06585241View on ClinicalTrials.gov

A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

PHASE4RecruitingINTERVENTIONAL
Enrollment

764

Participants

Timeline

Start Date

September 9, 2024

Primary Completion Date

May 7, 2026

Study Completion Date

May 7, 2026

Conditions
SARS-CoV-2
Interventions
BIOLOGICAL

mRNA-1273 Variant-containing Formulation

Sterile liquid for injection

Trial Locations (5)

30030

RECRUITING

CenExel, Decatur

30331

RECRUITING

CenExel, Atlanta

39503

RECRUITING

Velocity Clinical Research, Gulfport

68134

RECRUITING

Velocity Clinical Research, Omaha

70809

RECRUITING

Velocity Clinical Research, Baton Rouge

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY